Trial Purpose

The purpose of this study is to evaluate pathological complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) [Cohort A] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) [Cohort B].

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER

NCT06036836

EudraCT Number

2023-505022-34

When you talk with your doctor or clinical trial team member, please have the trial identifier number or the EudraCT number available.

Resources

Eligibility

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Cutaneous Squamous Cell Carcinoma, Endometrial Cancer, Solid Tumor

Age Range Icon

Age Range

18+

Sex Icon

Sex

All

About the trial

All patients who enroll in the trial will receive medication while on the study.

Cutaneous Squamous Cell Carcinoma (cSCC) Patients

50% will receive MK-4280A (contains favezelimab and pembrolizumab) before and after surgery.

50% will receive pembrolizumab before and after surgery.

Endometrial Cancer (EC) Patients

50% will receive MK-4280A (contains favezelimab and pembrolizumab) and lenvatinib.

50% will receive pembrolizumab and lenvatinib.

Trial phase Icon Current trial phase

Trial Phase 2

In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.

Trial start Icon Trial start and end dates
  • Trial start date September 29, 2023
  • Estimated primary completion date March 9, 2027
  • Estimated trial completion date March 9, 2027

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

CLINICALTRIALS.GOV IDENTIFIER

NCT06036836

EudraCT Number

2023-505022-34

When you talk with your doctor or clinical trial team member, please have the trial identifier number or the EudraCT number available.

Taking part in a clinical trial is an important decision

If you are considering joining a clinical trial, first learn as much as you can about:

  • The investigational treatment that is being studied
  • What the risks and possible benefits are for participants

Talk to your doctor about the clinical trial before you decide to join.

Read our “What to Consider” page for more questions to ask and think about